Table 3 RP of immunotherapy related studies
From: Re-evaluating the risk factors for radiation pneumonitis in the era of immunotherapy
Drugs | Study | Published year | study type | No. of cases | Radiation dose(Gy) | RP rate(%) |
|---|---|---|---|---|---|---|
Durvalumab | Pacific study [83] | 2017 | Clinical Trial | 713 | 54–66 | 33.9 |
Moore [97] | 2020 | Clinical Trial | 39 | 60 | 54.0 | |
Inoue [98] | 2020 | retrospective study | 30 | 60–64 | 73.0 > 3Grade: 0 | |
Atezolizumab | Lin S H [95] | 2020 | Clinical Trial | 52 | 66 | P1:10.0;P2:16.0 |
Nivolumab | Peters S [94] | 2021 | Clinical Trial | 79 | 66 | > 3Grade: 11.7 |
ICI + RT | Botticella A [89] | 2019 | retrospective study | 318 | 50–60 | 16.7 |
Pembrolizumab | Verma V [127] | 2018 | retrospective study | 60 | 50–60 | > 3Grade: A:25;B:5;C:36 |
Keynote-001 [90] | 2017 | Clinical Trial | 550 | / | A:40;B:63 > 3Grade: A:12;B:17 | |
Durm G A [91] (Lun14-179) | 2020 | Clinical Trial | 93 | 59.4–66.6 | > 2Grade: 15.2 | |
Keynote-799 [92] | 2021 | Clinical Trial | 216 | 60 | A:17.9;B:7.8 > 3Grade: A:1.8;B:1.0; | |
Jabbour S K [93] | 2020 | Clinical Trial | 21 | 60 | 33.0 > 3Grade: 2.0 | |
ICI + SBRT | TIAN S [26] | 2019 | Clinical Trial | 117 | SBRT | 33.9 > 3Grade: 10.7 |